FI3494119T3 - Yhdisteitä ja koostumuksia ja niiden käyttötapoja - Google Patents
Yhdisteitä ja koostumuksia ja niiden käyttötapoja Download PDFInfo
- Publication number
- FI3494119T3 FI3494119T3 FIEP17835385.0T FI17835385T FI3494119T3 FI 3494119 T3 FI3494119 T3 FI 3494119T3 FI 17835385 T FI17835385 T FI 17835385T FI 3494119 T3 FI3494119 T3 FI 3494119T3
- Authority
- FI
- Finland
- Prior art keywords
- disorder
- syndrome
- disease
- pain
- disorders
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims 50
- 239000000203 mixture Substances 0.000 title claims 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 66
- 208000035475 disorder Diseases 0.000 claims 54
- 208000011580 syndromic disease Diseases 0.000 claims 32
- 208000002193 Pain Diseases 0.000 claims 29
- 150000003839 salts Chemical class 0.000 claims 29
- 208000020925 Bipolar disease Diseases 0.000 claims 28
- 208000028017 Psychotic disease Diseases 0.000 claims 27
- 229910052739 hydrogen Inorganic materials 0.000 claims 25
- 206010015037 epilepsy Diseases 0.000 claims 22
- 239000001257 hydrogen Substances 0.000 claims 21
- 206010010904 Convulsion Diseases 0.000 claims 20
- 208000014094 Dystonic disease Diseases 0.000 claims 20
- 208000010118 dystonia Diseases 0.000 claims 20
- 208000024827 Alzheimer disease Diseases 0.000 claims 19
- 208000019901 Anxiety disease Diseases 0.000 claims 19
- 206010034010 Parkinsonism Diseases 0.000 claims 18
- 239000003814 drug Substances 0.000 claims 18
- 229940079593 drug Drugs 0.000 claims 18
- 206010044565 Tremor Diseases 0.000 claims 17
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 16
- 201000000980 schizophrenia Diseases 0.000 claims 16
- 206010012289 Dementia Diseases 0.000 claims 15
- 208000018737 Parkinson disease Diseases 0.000 claims 15
- 208000010877 cognitive disease Diseases 0.000 claims 15
- 208000004296 neuralgia Diseases 0.000 claims 15
- 208000027089 Parkinsonian disease Diseases 0.000 claims 14
- 208000019116 sleep disease Diseases 0.000 claims 13
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 12
- 208000016285 Movement disease Diseases 0.000 claims 12
- 229910052731 fluorine Inorganic materials 0.000 claims 12
- 239000011737 fluorine Substances 0.000 claims 12
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 12
- 201000003631 narcolepsy Diseases 0.000 claims 12
- 208000033808 peripheral neuropathy Diseases 0.000 claims 12
- 208000012902 Nervous system disease Diseases 0.000 claims 11
- 208000024714 major depressive disease Diseases 0.000 claims 11
- 206010003591 Ataxia Diseases 0.000 claims 10
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 10
- 208000020401 Depressive disease Diseases 0.000 claims 10
- 208000037158 Partial Epilepsies Diseases 0.000 claims 10
- 230000016571 aggressive behavior Effects 0.000 claims 10
- 229910052801 chlorine Inorganic materials 0.000 claims 10
- 239000000460 chlorine Substances 0.000 claims 10
- 201000010099 disease Diseases 0.000 claims 10
- 239000000126 substance Substances 0.000 claims 10
- 208000012661 Dyskinesia Diseases 0.000 claims 9
- 208000007514 Herpes zoster Diseases 0.000 claims 9
- 230000001684 chronic effect Effects 0.000 claims 9
- 125000004093 cyano group Chemical group *C#N 0.000 claims 9
- 206010001497 Agitation Diseases 0.000 claims 8
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 8
- 206010019233 Headaches Diseases 0.000 claims 8
- 208000023105 Huntington disease Diseases 0.000 claims 8
- 208000025966 Neurological disease Diseases 0.000 claims 8
- 206010061334 Partial seizures Diseases 0.000 claims 8
- 238000013019 agitation Methods 0.000 claims 8
- 201000007186 focal epilepsy Diseases 0.000 claims 8
- 231100000869 headache Toxicity 0.000 claims 8
- 208000021722 neuropathic pain Diseases 0.000 claims 8
- 230000002085 persistent effect Effects 0.000 claims 8
- 208000020016 psychiatric disease Diseases 0.000 claims 8
- 208000024891 symptom Diseases 0.000 claims 8
- 208000000044 Amnesia Diseases 0.000 claims 7
- 208000006820 Arthralgia Diseases 0.000 claims 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 7
- 208000019695 Migraine disease Diseases 0.000 claims 7
- 208000027626 Neurocognitive disease Diseases 0.000 claims 7
- 230000036506 anxiety Effects 0.000 claims 7
- 206010027599 migraine Diseases 0.000 claims 7
- 230000000750 progressive effect Effects 0.000 claims 7
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 6
- 208000008035 Back Pain Diseases 0.000 claims 6
- 208000028698 Cognitive impairment Diseases 0.000 claims 6
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 6
- 208000004547 Hallucinations Diseases 0.000 claims 6
- 208000036572 Myoclonic epilepsy Diseases 0.000 claims 6
- 208000002033 Myoclonus Diseases 0.000 claims 6
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 6
- 201000001880 Sexual dysfunction Diseases 0.000 claims 6
- 206010043118 Tardive Dyskinesia Diseases 0.000 claims 6
- 206010043269 Tension headache Diseases 0.000 claims 6
- 208000008548 Tension-Type Headache Diseases 0.000 claims 6
- 206010044074 Torticollis Diseases 0.000 claims 6
- 201000004810 Vascular dementia Diseases 0.000 claims 6
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 6
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 6
- 206010027175 memory impairment Diseases 0.000 claims 6
- 201000001119 neuropathy Diseases 0.000 claims 6
- 230000007823 neuropathy Effects 0.000 claims 6
- 208000019906 panic disease Diseases 0.000 claims 6
- 208000022821 personality disease Diseases 0.000 claims 6
- 231100000872 sexual dysfunction Toxicity 0.000 claims 6
- 201000002859 sleep apnea Diseases 0.000 claims 6
- 208000020706 Autistic disease Diseases 0.000 claims 5
- 206010008748 Chorea Diseases 0.000 claims 5
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 claims 5
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 claims 5
- 208000028389 Nerve injury Diseases 0.000 claims 5
- 208000008589 Obesity Diseases 0.000 claims 5
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims 5
- 206010041349 Somnolence Diseases 0.000 claims 5
- 208000005392 Spasm Diseases 0.000 claims 5
- 230000001154 acute effect Effects 0.000 claims 5
- 208000029560 autism spectrum disease Diseases 0.000 claims 5
- 230000006735 deficit Effects 0.000 claims 5
- 208000024732 dysthymic disease Diseases 0.000 claims 5
- 206010022437 insomnia Diseases 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- 230000036651 mood Effects 0.000 claims 5
- 201000006417 multiple sclerosis Diseases 0.000 claims 5
- 230000008764 nerve damage Effects 0.000 claims 5
- 230000000926 neurological effect Effects 0.000 claims 5
- 235000020824 obesity Nutrition 0.000 claims 5
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 5
- 230000007958 sleep Effects 0.000 claims 5
- 208000002320 spinal muscular atrophy Diseases 0.000 claims 5
- 208000011117 substance-related disease Diseases 0.000 claims 5
- 208000023434 Alpers-Huttenlocher syndrome Diseases 0.000 claims 4
- 208000031091 Amnestic disease Diseases 0.000 claims 4
- 208000009575 Angelman syndrome Diseases 0.000 claims 4
- 206010003594 Ataxia telangiectasia Diseases 0.000 claims 4
- 239000004215 Carbon black (E152) Substances 0.000 claims 4
- 208000001573 Cataplexy Diseases 0.000 claims 4
- 201000001913 Childhood absence epilepsy Diseases 0.000 claims 4
- 208000006561 Cluster Headache Diseases 0.000 claims 4
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 claims 4
- 208000004986 Diffuse Cerebral Sclerosis of Schilder Diseases 0.000 claims 4
- 208000001654 Drug Resistant Epilepsy Diseases 0.000 claims 4
- 208000001640 Fibromyalgia Diseases 0.000 claims 4
- 208000011688 Generalised anxiety disease Diseases 0.000 claims 4
- 206010019468 Hemiplegia Diseases 0.000 claims 4
- 206010065390 Inflammatory pain Diseases 0.000 claims 4
- 208000003618 Intervertebral Disc Displacement Diseases 0.000 claims 4
- 201000005802 Landau-Kleffner Syndrome Diseases 0.000 claims 4
- 201000006792 Lennox-Gastaut syndrome Diseases 0.000 claims 4
- 208000019022 Mood disease Diseases 0.000 claims 4
- 208000009571 Myoclonic Cerebellar Dyssynergia Diseases 0.000 claims 4
- 208000001294 Nociceptive Pain Diseases 0.000 claims 4
- 206010073211 Postural tremor Diseases 0.000 claims 4
- 208000009144 Pure autonomic failure Diseases 0.000 claims 4
- 208000005793 Restless legs syndrome Diseases 0.000 claims 4
- 206010070834 Sensitisation Diseases 0.000 claims 4
- 206010041250 Social phobia Diseases 0.000 claims 4
- 208000000323 Tourette Syndrome Diseases 0.000 claims 4
- 208000016620 Tourette disease Diseases 0.000 claims 4
- 208000003554 absence epilepsy Diseases 0.000 claims 4
- 125000001931 aliphatic group Chemical group 0.000 claims 4
- 230000006986 amnesia Effects 0.000 claims 4
- 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 claims 4
- 230000006399 behavior Effects 0.000 claims 4
- 206010007776 catatonia Diseases 0.000 claims 4
- 208000012601 choreatic disease Diseases 0.000 claims 4
- 206010012601 diabetes mellitus Diseases 0.000 claims 4
- 235000014632 disordered eating Nutrition 0.000 claims 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims 4
- 201000009028 early myoclonic encephalopathy Diseases 0.000 claims 4
- 206010014599 encephalitis Diseases 0.000 claims 4
- 201000002904 focal dystonia Diseases 0.000 claims 4
- 208000028316 focal seizure Diseases 0.000 claims 4
- 208000029364 generalized anxiety disease Diseases 0.000 claims 4
- 229930195733 hydrocarbon Natural products 0.000 claims 4
- 150000002430 hydrocarbons Chemical class 0.000 claims 4
- 230000015654 memory Effects 0.000 claims 4
- 208000027061 mild cognitive impairment Diseases 0.000 claims 4
- 201000011540 mitochondrial DNA depletion syndrome 4a Diseases 0.000 claims 4
- 208000033510 neuroaxonal dystrophy Diseases 0.000 claims 4
- 230000008313 sensitization Effects 0.000 claims 4
- 208000020685 sleep-wake disease Diseases 0.000 claims 4
- 210000005070 sphincter Anatomy 0.000 claims 4
- 206010001541 Akinesia Diseases 0.000 claims 3
- 208000037857 Alzheimer's disease agitation Diseases 0.000 claims 3
- 206010003805 Autism Diseases 0.000 claims 3
- 206010068597 Bulbospinal muscular atrophy congenital Diseases 0.000 claims 3
- 208000001387 Causalgia Diseases 0.000 claims 3
- 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 claims 3
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims 3
- 208000013586 Complex regional pain syndrome type 1 Diseases 0.000 claims 3
- 208000027691 Conduct disease Diseases 0.000 claims 3
- 206010012218 Delirium Diseases 0.000 claims 3
- 208000012239 Developmental disease Diseases 0.000 claims 3
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 3
- 208000026331 Disruptive, Impulse Control, and Conduct disease Diseases 0.000 claims 3
- 201000010374 Down Syndrome Diseases 0.000 claims 3
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 3
- 208000017463 Infantile neuroaxonal dystrophy Diseases 0.000 claims 3
- 208000027747 Kennedy disease Diseases 0.000 claims 3
- 208000005870 Lafora disease Diseases 0.000 claims 3
- 208000020358 Learning disease Diseases 0.000 claims 3
- 208000004983 Phantom Limb Diseases 0.000 claims 3
- 206010056238 Phantom pain Diseases 0.000 claims 3
- 208000027030 Premenstrual dysphoric disease Diseases 0.000 claims 3
- 208000033063 Progressive myoclonic epilepsy Diseases 0.000 claims 3
- 208000006262 Psychological Sexual Dysfunctions Diseases 0.000 claims 3
- 206010071141 Rasmussen encephalitis Diseases 0.000 claims 3
- 208000004160 Rasmussen subacute encephalitis Diseases 0.000 claims 3
- 201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 claims 3
- 208000005439 Sleep paralysis Diseases 0.000 claims 3
- 208000006011 Stroke Diseases 0.000 claims 3
- 208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 claims 3
- 230000037007 arousal Effects 0.000 claims 3
- 230000003542 behavioural effect Effects 0.000 claims 3
- 208000003295 carpal tunnel syndrome Diseases 0.000 claims 3
- 208000024825 childhood disintegrative disease Diseases 0.000 claims 3
- 230000001149 cognitive effect Effects 0.000 claims 3
- 230000003920 cognitive function Effects 0.000 claims 3
- 208000014439 complex regional pain syndrome type 2 Diseases 0.000 claims 3
- 230000008602 contraction Effects 0.000 claims 3
- 208000026725 cyclothymic disease Diseases 0.000 claims 3
- 230000007850 degeneration Effects 0.000 claims 3
- 201000006517 essential tremor Diseases 0.000 claims 3
- 230000005032 impulse control Effects 0.000 claims 3
- 208000014674 injury Diseases 0.000 claims 3
- 230000013016 learning Effects 0.000 claims 3
- 201000003723 learning disability Diseases 0.000 claims 3
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims 3
- 230000004770 neurodegeneration Effects 0.000 claims 3
- 201000007599 neurodegeneration with brain iron accumulation 2a Diseases 0.000 claims 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims 3
- 239000003176 neuroleptic agent Substances 0.000 claims 3
- 230000000701 neuroleptic effect Effects 0.000 claims 3
- 208000002851 paranoid schizophrenia Diseases 0.000 claims 3
- 230000008447 perception Effects 0.000 claims 3
- 208000033300 perinatal asphyxia Diseases 0.000 claims 3
- 208000026961 psychosexual disease Diseases 0.000 claims 3
- 230000001568 sexual effect Effects 0.000 claims 3
- 210000000278 spinal cord Anatomy 0.000 claims 3
- 201000009032 substance abuse Diseases 0.000 claims 3
- 231100000736 substance abuse Toxicity 0.000 claims 3
- 230000002889 sympathetic effect Effects 0.000 claims 3
- 230000008733 trauma Effects 0.000 claims 3
- 230000001457 vasomotor Effects 0.000 claims 3
- 230000001755 vocal effect Effects 0.000 claims 3
- 208000030507 AIDS Diseases 0.000 claims 2
- 206010052075 Acquired epileptic aphasia Diseases 0.000 claims 2
- 201000011452 Adrenoleukodystrophy Diseases 0.000 claims 2
- 208000006888 Agnosia Diseases 0.000 claims 2
- 241001047040 Agnosia Species 0.000 claims 2
- 208000008811 Agoraphobia Diseases 0.000 claims 2
- 208000011403 Alexander disease Diseases 0.000 claims 2
- 241001237754 Algia Species 0.000 claims 2
- 206010002942 Apathy Diseases 0.000 claims 2
- 206010003062 Apraxia Diseases 0.000 claims 2
- 102000007371 Ataxin-3 Human genes 0.000 claims 2
- 108010032947 Ataxin-3 Proteins 0.000 claims 2
- 208000009017 Athetosis Diseases 0.000 claims 2
- 208000030169 Benign childhood occipital epilepsy, Panayiotopoulos type Diseases 0.000 claims 2
- 208000034577 Benign intracranial hypertension Diseases 0.000 claims 2
- 208000021465 Brief psychotic disease Diseases 0.000 claims 2
- 208000029402 Bulbospinal muscular atrophy Diseases 0.000 claims 2
- 206010006550 Bulimia nervosa Diseases 0.000 claims 2
- 208000010482 CADASIL Diseases 0.000 claims 2
- 208000013576 CDKL5 disease Diseases 0.000 claims 2
- 206010058019 Cancer Pain Diseases 0.000 claims 2
- 201000001601 Capgras syndrome Diseases 0.000 claims 2
- 208000009810 Catatonic Schizophrenia Diseases 0.000 claims 2
- 206010064012 Central pain syndrome Diseases 0.000 claims 2
- 208000033221 Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy Diseases 0.000 claims 2
- 208000033935 Cerebral autosomal dominant arteriopathy-subcortical infarcts-leukoencephalopathy Diseases 0.000 claims 2
- 201000006867 Charcot-Marie-Tooth disease type 4 Diseases 0.000 claims 2
- 206010010071 Coma Diseases 0.000 claims 2
- 208000011990 Corticobasal Degeneration Diseases 0.000 claims 2
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims 2
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims 2
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims 2
- 206010012245 Delusion of replacement Diseases 0.000 claims 2
- 208000024254 Delusional disease Diseases 0.000 claims 2
- 206010067889 Dementia with Lewy bodies Diseases 0.000 claims 2
- 206010012335 Dependence Diseases 0.000 claims 2
- 208000019246 Developmental coordination disease Diseases 0.000 claims 2
- 206010013496 Disturbance in attention Diseases 0.000 claims 2
- 201000007547 Dravet syndrome Diseases 0.000 claims 2
- 206010013952 Dysphonia Diseases 0.000 claims 2
- 206010013954 Dysphoria Diseases 0.000 claims 2
- 208000005819 Dystonia Musculorum Deformans Diseases 0.000 claims 2
- 201000008009 Early infantile epileptic encephalopathy Diseases 0.000 claims 2
- 206010071545 Early infantile epileptic encephalopathy with burst-suppression Diseases 0.000 claims 2
- 208000030814 Eating disease Diseases 0.000 claims 2
- 208000016132 Epilepsy with myoclonic absences Diseases 0.000 claims 2
- 208000010228 Erectile Dysfunction Diseases 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 206010016059 Facial pain Diseases 0.000 claims 2
- 208000002091 Febrile Seizures Diseases 0.000 claims 2
- 208000010235 Food Addiction Diseases 0.000 claims 2
- 208000024412 Friedreich ataxia Diseases 0.000 claims 2
- 201000009010 Frontal lobe epilepsy Diseases 0.000 claims 2
- 208000007686 GLUT1 deficiency syndrome Diseases 0.000 claims 2
- 208000003078 Generalized Epilepsy Diseases 0.000 claims 2
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims 2
- 108700006771 Glut1 Deficiency Syndrome Proteins 0.000 claims 2
- 201000005569 Gout Diseases 0.000 claims 2
- 208000014901 Graham Little-Piccardi-Lassueur syndrome Diseases 0.000 claims 2
- 208000034308 Grand mal convulsion Diseases 0.000 claims 2
- 208000031886 HIV Infections Diseases 0.000 claims 2
- 208000006411 Hereditary Sensory and Motor Neuropathy Diseases 0.000 claims 2
- 206010063629 Hippocampal sclerosis Diseases 0.000 claims 2
- 206010069099 Holmes tremor Diseases 0.000 claims 2
- 101001072243 Homo sapiens Protocadherin-19 Proteins 0.000 claims 2
- 101000625846 Homo sapiens TBC domain-containing protein kinase-like protein Proteins 0.000 claims 2
- 208000033830 Hot Flashes Diseases 0.000 claims 2
- 206010060800 Hot flush Diseases 0.000 claims 2
- 208000000269 Hyperkinesis Diseases 0.000 claims 2
- 206010071081 Idiopathic generalised epilepsy Diseases 0.000 claims 2
- 208000018127 Idiopathic intracranial hypertension Diseases 0.000 claims 2
- 206010021750 Infantile Spasms Diseases 0.000 claims 2
- 208000035899 Infantile spasms syndrome Diseases 0.000 claims 2
- 206010061246 Intervertebral disc degeneration Diseases 0.000 claims 2
- 206010050296 Intervertebral disc protrusion Diseases 0.000 claims 2
- 208000015592 Involuntary movements Diseases 0.000 claims 2
- 208000001456 Jet Lag Syndrome Diseases 0.000 claims 2
- 208000014161 Lafora myoclonic epilepsy Diseases 0.000 claims 2
- 201000002832 Lewy body dementia Diseases 0.000 claims 2
- 206010050219 Lumbar radiculopathy Diseases 0.000 claims 2
- 208000016604 Lyme disease Diseases 0.000 claims 2
- 208000002569 Machado-Joseph Disease Diseases 0.000 claims 2
- 206010026749 Mania Diseases 0.000 claims 2
- 102000009030 Member 1 Subfamily D ATP Binding Cassette Transporter Human genes 0.000 claims 2
- 108010049137 Member 1 Subfamily D ATP Binding Cassette Transporter Proteins 0.000 claims 2
- 208000026139 Memory disease Diseases 0.000 claims 2
- 201000009906 Meningitis Diseases 0.000 claims 2
- 208000000060 Migraine with aura Diseases 0.000 claims 2
- 208000019896 Motor Skills disease Diseases 0.000 claims 2
- 208000005314 Multi-Infarct Dementia Diseases 0.000 claims 2
- 208000001089 Multiple system atrophy Diseases 0.000 claims 2
- 208000007101 Muscle Cramp Diseases 0.000 claims 2
- 208000008238 Muscle Spasticity Diseases 0.000 claims 2
- 208000010428 Muscle Weakness Diseases 0.000 claims 2
- 208000029578 Muscle disease Diseases 0.000 claims 2
- 206010028347 Muscle twitching Diseases 0.000 claims 2
- 208000021642 Muscular disease Diseases 0.000 claims 2
- 206010028372 Muscular weakness Diseases 0.000 claims 2
- 206010028391 Musculoskeletal Pain Diseases 0.000 claims 2
- 208000037004 Myoclonic-astatic epilepsy Diseases 0.000 claims 2
- 208000037212 Neonatal hypoxic and ischemic brain injury Diseases 0.000 claims 2
- 208000005890 Neuroma Diseases 0.000 claims 2
- 208000032461 Panayiotopoulos type benign childhood occipital epilepsy Diseases 0.000 claims 2
- 206010033664 Panic attack Diseases 0.000 claims 2
- 206010033799 Paralysis Diseases 0.000 claims 2
- 208000012075 Paroxysmal dystonia Diseases 0.000 claims 2
- 208000023610 Pelvic Floor disease Diseases 0.000 claims 2
- 208000000450 Pelvic Pain Diseases 0.000 claims 2
- 208000012202 Pervasive developmental disease Diseases 0.000 claims 2
- 206010034759 Petit mal epilepsy Diseases 0.000 claims 2
- 206010034912 Phobia Diseases 0.000 claims 2
- 241001482237 Pica Species 0.000 claims 2
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims 2
- 208000008713 Piriformis Muscle Syndrome Diseases 0.000 claims 2
- 206010036313 Post-traumatic headache Diseases 0.000 claims 2
- 206010071366 Post-traumatic neck syndrome Diseases 0.000 claims 2
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims 2
- 206010036618 Premenstrual syndrome Diseases 0.000 claims 2
- 208000032319 Primary lateral sclerosis Diseases 0.000 claims 2
- 208000024777 Prion disease Diseases 0.000 claims 2
- 102100036389 Protocadherin-19 Human genes 0.000 claims 2
- 208000032225 Proximal spinal muscular atrophy type 1 Diseases 0.000 claims 2
- 208000033526 Proximal spinal muscular atrophy type 3 Diseases 0.000 claims 2
- 208000014370 Psychogenic movement disease Diseases 0.000 claims 2
- 208000025535 REM sleep behavior disease Diseases 0.000 claims 2
- 208000028665 Reactive Attachment disease Diseases 0.000 claims 2
- 206010038743 Restlessness Diseases 0.000 claims 2
- 208000006289 Rett Syndrome Diseases 0.000 claims 2
- 208000007077 SUNCT syndrome Diseases 0.000 claims 2
- 208000036754 Schizophrenia, catatonic type Diseases 0.000 claims 2
- 208000008765 Sciatica Diseases 0.000 claims 2
- 208000034189 Sclerosis Diseases 0.000 claims 2
- 208000008039 Secondary Parkinson Disease Diseases 0.000 claims 2
- 208000018642 Semantic dementia Diseases 0.000 claims 2
- 206010039966 Senile dementia Diseases 0.000 claims 2
- 208000000810 Separation Anxiety Diseases 0.000 claims 2
- 206010073677 Severe myoclonic epilepsy of infancy Diseases 0.000 claims 2
- 208000009106 Shy-Drager Syndrome Diseases 0.000 claims 2
- 208000010340 Sleep Deprivation Diseases 0.000 claims 2
- 206010067672 Spasmodic dysphonia Diseases 0.000 claims 2
- 208000021392 Specific Learning disease Diseases 0.000 claims 2
- 208000003954 Spinal Muscular Atrophies of Childhood Diseases 0.000 claims 2
- 208000036834 Spinocerebellar ataxia type 3 Diseases 0.000 claims 2
- 206010042008 Stereotypy Diseases 0.000 claims 2
- 206010042265 Sturge-Weber Syndrome Diseases 0.000 claims 2
- 102100024750 TBC domain-containing protein kinase-like protein Human genes 0.000 claims 2
- 206010051526 Tolosa-Hunt syndrome Diseases 0.000 claims 2
- 208000006633 Tonic-Clonic Epilepsy Diseases 0.000 claims 2
- 208000031674 Traumatic Acute Stress disease Diseases 0.000 claims 2
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 2
- 206010046298 Upper motor neurone lesion Diseases 0.000 claims 2
- 206010063661 Vascular encephalopathy Diseases 0.000 claims 2
- 206010047700 Vomiting Diseases 0.000 claims 2
- 206010047791 Vulvovaginal dryness Diseases 0.000 claims 2
- 201000006791 West syndrome Diseases 0.000 claims 2
- 208000021567 Whiplash injury Diseases 0.000 claims 2
- 208000028311 absence seizure Diseases 0.000 claims 2
- 208000005298 acute pain Diseases 0.000 claims 2
- 208000026345 acute stress disease Diseases 0.000 claims 2
- 125000003282 alkyl amino group Chemical group 0.000 claims 2
- 201000007201 aphasia Diseases 0.000 claims 2
- 206010003074 arachnoiditis Diseases 0.000 claims 2
- 208000003464 asthenopia Diseases 0.000 claims 2
- 201000002922 basal ganglia calcification Diseases 0.000 claims 2
- 208000016791 bilateral striopallidodentate calcinosis Diseases 0.000 claims 2
- 208000028683 bipolar I disease Diseases 0.000 claims 2
- 208000016886 cerebral arteriopathy with subcortical infarcts and leukoencephalopathy Diseases 0.000 claims 2
- 230000002490 cerebral effect Effects 0.000 claims 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims 2
- 201000002866 cervical dystonia Diseases 0.000 claims 2
- 238000002512 chemotherapy Methods 0.000 claims 2
- 208000033205 childhood epilepsy with centrotemporal spikes Diseases 0.000 claims 2
- 208000022371 chronic pain syndrome Diseases 0.000 claims 2
- 208000018912 cluster headache syndrome Diseases 0.000 claims 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims 2
- 230000019771 cognition Effects 0.000 claims 2
- 206010010121 compartment syndrome Diseases 0.000 claims 2
- 208000015134 congenital hypothalamic hamartoma syndrome Diseases 0.000 claims 2
- 239000013256 coordination polymer Substances 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 208000018180 degenerative disc disease Diseases 0.000 claims 2
- 230000003001 depressive effect Effects 0.000 claims 2
- 208000013257 developmental and epileptic encephalopathy Diseases 0.000 claims 2
- 229960003638 dopamine Drugs 0.000 claims 2
- 208000009985 drug-induced dyskinesia Diseases 0.000 claims 2
- 230000004064 dysfunction Effects 0.000 claims 2
- 230000008482 dysregulation Effects 0.000 claims 2
- 230000000632 dystonic effect Effects 0.000 claims 2
- 208000025688 early-onset autosomal dominant Alzheimer disease Diseases 0.000 claims 2
- 208000016570 early-onset generalized limb-onset dystonia Diseases 0.000 claims 2
- 230000008451 emotion Effects 0.000 claims 2
- 201000003104 endogenous depression Diseases 0.000 claims 2
- 201000002933 epilepsy with generalized tonic-clonic seizures Diseases 0.000 claims 2
- 230000001037 epileptic effect Effects 0.000 claims 2
- 210000003414 extremity Anatomy 0.000 claims 2
- 208000011149 familial idiopathic torsion dystonia Diseases 0.000 claims 2
- 208000004967 femoral neuropathy Diseases 0.000 claims 2
- 201000002886 generalized dystonia Diseases 0.000 claims 2
- 230000002068 genetic effect Effects 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 208000021995 hereditary motor and sensory neuropathy Diseases 0.000 claims 2
- 208000012285 hip pain Diseases 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 208000013403 hyperactivity Diseases 0.000 claims 2
- 230000003483 hypokinetic effect Effects 0.000 claims 2
- 201000001993 idiopathic generalized epilepsy Diseases 0.000 claims 2
- 208000011110 idiopathic torsion dystonia Diseases 0.000 claims 2
- 230000001771 impaired effect Effects 0.000 claims 2
- 201000001881 impotence Diseases 0.000 claims 2
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 2
- -1 inhalants Chemical compound 0.000 claims 2
- 208000021600 intervertebral disc degenerative disease Diseases 0.000 claims 2
- 208000028867 ischemia Diseases 0.000 claims 2
- HEBMCVBCEDMUOF-UHFFFAOYSA-N isochromane Chemical compound C1=CC=C2COCCC2=C1 HEBMCVBCEDMUOF-UHFFFAOYSA-N 0.000 claims 2
- 208000033915 jet lag type circadian rhythm sleep disease Diseases 0.000 claims 2
- 208000024765 knee pain Diseases 0.000 claims 2
- 201000010901 lateral sclerosis Diseases 0.000 claims 2
- 230000006984 memory degeneration Effects 0.000 claims 2
- 208000023060 memory loss Diseases 0.000 claims 2
- 208000005264 motor neuron disease Diseases 0.000 claims 2
- 201000005545 motor peripheral neuropathy Diseases 0.000 claims 2
- 201000000585 muscular atrophy Diseases 0.000 claims 2
- 230000017311 musculoskeletal movement, spinal reflex action Effects 0.000 claims 2
- 230000002151 myoclonic effect Effects 0.000 claims 2
- 208000028492 myoclonic seizure Diseases 0.000 claims 2
- 208000016313 myoclonic-astastic epilepsy Diseases 0.000 claims 2
- 208000019382 nerve compression syndrome Diseases 0.000 claims 2
- 206010029410 night sweats Diseases 0.000 claims 2
- 230000036565 night sweats Effects 0.000 claims 2
- 230000000422 nocturnal effect Effects 0.000 claims 2
- 201000001909 oculomotor nerve paralysis Diseases 0.000 claims 2
- 201000002851 oromandibular dystonia Diseases 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 208000021090 palsy Diseases 0.000 claims 2
- 208000002593 pantothenate kinase-associated neurodegeneration Diseases 0.000 claims 2
- 210000001152 parietal lobe Anatomy 0.000 claims 2
- 230000035515 penetration Effects 0.000 claims 2
- 208000027232 peripheral nervous system disease Diseases 0.000 claims 2
- 201000003040 photosensitive epilepsy Diseases 0.000 claims 2
- 206010049433 piriformis syndrome Diseases 0.000 claims 2
- 206010036596 premature ejaculation Diseases 0.000 claims 2
- 201000008752 progressive muscular atrophy Diseases 0.000 claims 2
- 201000000196 pseudobulbar palsy Diseases 0.000 claims 2
- 208000001381 pseudotumor cerebri Diseases 0.000 claims 2
- 230000001107 psychogenic effect Effects 0.000 claims 2
- 230000036385 rapid eye movement (rem) sleep Effects 0.000 claims 2
- 208000000029 referred pain Diseases 0.000 claims 2
- 230000011514 reflex Effects 0.000 claims 2
- 201000005070 reflex epilepsy Diseases 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 231100000241 scar Toxicity 0.000 claims 2
- 208000022610 schizoaffective disease Diseases 0.000 claims 2
- 206010039722 scoliosis Diseases 0.000 claims 2
- 208000025874 separation anxiety disease Diseases 0.000 claims 2
- 230000011664 signaling Effects 0.000 claims 2
- 201000002849 spasmodic dystonia Diseases 0.000 claims 2
- 230000001148 spastic effect Effects 0.000 claims 2
- 201000001716 specific phobia Diseases 0.000 claims 2
- 238000001228 spectrum Methods 0.000 claims 2
- 208000027765 speech disease Diseases 0.000 claims 2
- 210000001032 spinal nerve Anatomy 0.000 claims 2
- 208000005198 spinal stenosis Diseases 0.000 claims 2
- 208000005809 status epilepticus Diseases 0.000 claims 2
- 208000013623 stereotypic movement disease Diseases 0.000 claims 2
- 230000002739 subcortical effect Effects 0.000 claims 2
- 201000006137 substance-induced psychosis Diseases 0.000 claims 2
- 210000003478 temporal lobe Anatomy 0.000 claims 2
- 201000008914 temporal lobe epilepsy Diseases 0.000 claims 2
- 208000016686 tic disease Diseases 0.000 claims 2
- 208000028325 tonic-clonic seizure Diseases 0.000 claims 2
- 230000009529 traumatic brain injury Effects 0.000 claims 2
- 206010044652 trigeminal neuralgia Diseases 0.000 claims 2
- 208000032471 type 1 spinal muscular atrophy Diseases 0.000 claims 2
- 208000032527 type III spinal muscular atrophy Diseases 0.000 claims 2
- 230000002792 vascular Effects 0.000 claims 2
- 208000009935 visceral pain Diseases 0.000 claims 2
- 230000031836 visual learning Effects 0.000 claims 2
- 230000008673 vomiting Effects 0.000 claims 2
- 230000003936 working memory Effects 0.000 claims 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 1
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 1
- 208000024341 Aicardi syndrome Diseases 0.000 claims 1
- 208000031277 Amaurotic familial idiocy Diseases 0.000 claims 1
- 208000007415 Anhedonia Diseases 0.000 claims 1
- 208000027559 Appetite disease Diseases 0.000 claims 1
- 208000036640 Asperger disease Diseases 0.000 claims 1
- 201000006062 Asperger syndrome Diseases 0.000 claims 1
- 208000027448 Attention Deficit and Disruptive Behavior disease Diseases 0.000 claims 1
- 208000035183 Benign hereditary chorea Diseases 0.000 claims 1
- 206010048962 Brain oedema Diseases 0.000 claims 1
- 208000011597 CGF1 Diseases 0.000 claims 1
- 208000009132 Catalepsy Diseases 0.000 claims 1
- 201000008992 Charcot-Marie-Tooth disease type 1B Diseases 0.000 claims 1
- 206010011878 Deafness Diseases 0.000 claims 1
- 206010012209 Delayed sleep phase Diseases 0.000 claims 1
- 206010012239 Delusion Diseases 0.000 claims 1
- 206010012374 Depressed mood Diseases 0.000 claims 1
- 206010065701 Dermatillomania Diseases 0.000 claims 1
- 206010013142 Disinhibition Diseases 0.000 claims 1
- 208000001495 Disorganized Schizophrenia Diseases 0.000 claims 1
- 208000004483 Dyspareunia Diseases 0.000 claims 1
- 206010015535 Euphoric mood Diseases 0.000 claims 1
- 208000005741 Failed Back Surgery Syndrome Diseases 0.000 claims 1
- 208000001836 Firesetting Behavior Diseases 0.000 claims 1
- 206010016845 Foetal alcohol syndrome Diseases 0.000 claims 1
- 102100035428 Formiminotransferase N-terminal subdomain-containing protein Human genes 0.000 claims 1
- 208000001914 Fragile X syndrome Diseases 0.000 claims 1
- 206010018671 Grandiosity Diseases 0.000 claims 1
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 claims 1
- 208000014513 Hoarding disease Diseases 0.000 claims 1
- 101000877728 Homo sapiens Formiminotransferase N-terminal subdomain-containing protein Proteins 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 208000030990 Impulse-control disease Diseases 0.000 claims 1
- 206010021703 Indifference Diseases 0.000 claims 1
- 206010024264 Lethargy Diseases 0.000 claims 1
- 208000030431 Male orgasmic disease Diseases 0.000 claims 1
- 208000019430 Motor disease Diseases 0.000 claims 1
- 206010028403 Mutism Diseases 0.000 claims 1
- 206010061533 Myotonia Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000009668 Neurobehavioral Manifestations Diseases 0.000 claims 1
- 201000005625 Neuroleptic malignant syndrome Diseases 0.000 claims 1
- 208000002537 Neuronal Ceroid-Lipofuscinoses Diseases 0.000 claims 1
- 208000000224 Night Terrors Diseases 0.000 claims 1
- 208000008705 Nocturnal Myoclonus Syndrome Diseases 0.000 claims 1
- 241000232971 Passer domesticus Species 0.000 claims 1
- 208000024571 Pick disease Diseases 0.000 claims 1
- 206010057239 Post laminectomy syndrome Diseases 0.000 claims 1
- 201000009916 Postpartum depression Diseases 0.000 claims 1
- 208000033522 Proximal spinal muscular atrophy type 2 Diseases 0.000 claims 1
- 208000001431 Psychomotor Agitation Diseases 0.000 claims 1
- 208000029808 Psychomotor disease Diseases 0.000 claims 1
- 206010061921 Psychotic disorder due to a general medical condition Diseases 0.000 claims 1
- 206010059604 Radicular pain Diseases 0.000 claims 1
- 206010071390 Resting tremor Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 208000036752 Schizophrenia, paranoid type Diseases 0.000 claims 1
- 206010039917 Selective mutism Diseases 0.000 claims 1
- 206010041347 Somnambulism Diseases 0.000 claims 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims 1
- 208000011962 Substance-induced mood disease Diseases 0.000 claims 1
- 231100000395 Substance-induced mood disorder Toxicity 0.000 claims 1
- 208000011963 Substance-induced psychotic disease Diseases 0.000 claims 1
- 231100000393 Substance-induced psychotic disorder Toxicity 0.000 claims 1
- 208000027522 Sydenham chorea Diseases 0.000 claims 1
- 208000009205 Tinnitus Diseases 0.000 claims 1
- 208000028552 Treatment-Resistant Depressive disease Diseases 0.000 claims 1
- 206010046543 Urinary incontinence Diseases 0.000 claims 1
- 206010047853 Waxy flexibility Diseases 0.000 claims 1
- 208000026481 Werdnig-Hoffmann disease Diseases 0.000 claims 1
- 208000018839 Wilson disease Diseases 0.000 claims 1
- 208000012826 adjustment disease Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000007000 age related cognitive decline Effects 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 208000024823 antisocial personality disease Diseases 0.000 claims 1
- 239000002249 anxiolytic agent Substances 0.000 claims 1
- 230000000949 anxiolytic effect Effects 0.000 claims 1
- 229940005530 anxiolytics Drugs 0.000 claims 1
- 230000002917 arthritic effect Effects 0.000 claims 1
- 208000025748 atypical depressive disease Diseases 0.000 claims 1
- 210000004227 basal ganglia Anatomy 0.000 claims 1
- 208000013404 behavioral symptom Diseases 0.000 claims 1
- 208000004288 benign familial chorea Diseases 0.000 claims 1
- 208000022257 bipolar II disease Diseases 0.000 claims 1
- 208000022266 body dysmorphic disease Diseases 0.000 claims 1
- 208000006752 brain edema Diseases 0.000 claims 1
- 208000029028 brain injury Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000005779 cell damage Effects 0.000 claims 1
- 208000037887 cell injury Diseases 0.000 claims 1
- 208000007118 chronic progressive multiple sclerosis Diseases 0.000 claims 1
- 208000013114 circling movement Diseases 0.000 claims 1
- 229960003920 cocaine Drugs 0.000 claims 1
- 208000030251 communication disease Diseases 0.000 claims 1
- 230000002920 convulsive effect Effects 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 231100000868 delusion Toxicity 0.000 claims 1
- 206010013461 dissociative amnesia Diseases 0.000 claims 1
- 208000002173 dizziness Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000002545 drug psychosis Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000002743 euphoric effect Effects 0.000 claims 1
- 231100000040 eye damage Toxicity 0.000 claims 1
- 206010016256 fatigue Diseases 0.000 claims 1
- 208000026934 fetal alcohol spectrum disease Diseases 0.000 claims 1
- 201000007794 fetal alcohol syndrome Diseases 0.000 claims 1
- 208000020823 focal stiff limb syndrome Diseases 0.000 claims 1
- 230000006870 function Effects 0.000 claims 1
- 239000000380 hallucinogen Substances 0.000 claims 1
- 230000005802 health problem Effects 0.000 claims 1
- 230000010370 hearing loss Effects 0.000 claims 1
- 231100000888 hearing loss Toxicity 0.000 claims 1
- 208000016354 hearing loss disease Diseases 0.000 claims 1
- 206010020765 hypersomnia Diseases 0.000 claims 1
- 239000003326 hypnotic agent Substances 0.000 claims 1
- 230000000147 hypnotic effect Effects 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 201000004197 inhibited female orgasm Diseases 0.000 claims 1
- 201000000068 inhibited male orgasm Diseases 0.000 claims 1
- 208000015046 intermittent explosive disease Diseases 0.000 claims 1
- 208000017476 juvenile neuronal ceroid lipofuscinosis Diseases 0.000 claims 1
- 201000004815 juvenile spinal muscular atrophy Diseases 0.000 claims 1
- 206010023461 kleptomania Diseases 0.000 claims 1
- 230000006742 locomotor activity Effects 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 208000015421 male orgasm disease Diseases 0.000 claims 1
- 240000004308 marijuana Species 0.000 claims 1
- 238000002483 medication Methods 0.000 claims 1
- 201000003995 melancholia Diseases 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 208000007431 neuroacanthocytosis Diseases 0.000 claims 1
- 230000000626 neurodegenerative effect Effects 0.000 claims 1
- 208000037860 neuroleptic-induced Akathisia Diseases 0.000 claims 1
- 210000002569 neuron Anatomy 0.000 claims 1
- 201000007607 neuronal ceroid lipofuscinosis 3 Diseases 0.000 claims 1
- 229960002715 nicotine Drugs 0.000 claims 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims 1
- 208000005346 nocturnal enuresis Diseases 0.000 claims 1
- 208000013651 non-24-hour sleep-wake syndrome Diseases 0.000 claims 1
- 208000001797 obstructive sleep apnea Diseases 0.000 claims 1
- 229940005483 opioid analgesics Drugs 0.000 claims 1
- 208000024196 oppositional defiant disease Diseases 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 208000023515 periodic limb movement disease Diseases 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 claims 1
- 229950010883 phencyclidine Drugs 0.000 claims 1
- 230000004793 poor memory Effects 0.000 claims 1
- 210000002442 prefrontal cortex Anatomy 0.000 claims 1
- 206010063401 primary progressive multiple sclerosis Diseases 0.000 claims 1
- 201000001204 progressive myoclonus epilepsy Diseases 0.000 claims 1
- 201000002274 psychologic vaginismus Diseases 0.000 claims 1
- 201000004645 pyromania Diseases 0.000 claims 1
- 208000012672 seasonal affective disease Diseases 0.000 claims 1
- 239000000932 sedative agent Substances 0.000 claims 1
- 229940125723 sedative agent Drugs 0.000 claims 1
- 230000035946 sexual desire Effects 0.000 claims 1
- 210000003625 skull Anatomy 0.000 claims 1
- 210000001154 skull base Anatomy 0.000 claims 1
- 230000004039 social cognition Effects 0.000 claims 1
- 230000000392 somatic effect Effects 0.000 claims 1
- 201000006152 substance dependence Diseases 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 230000002459 sustained effect Effects 0.000 claims 1
- 231100000886 tinnitus Toxicity 0.000 claims 1
- 208000002271 trichotillomania Diseases 0.000 claims 1
- 208000032521 type II spinal muscular atrophy Diseases 0.000 claims 1
- 239000003981 vehicle Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/76—Benzo[c]pyrans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
- C07D313/02—Seven-membered rings
- C07D313/06—Seven-membered rings condensed with carbocyclic rings or ring systems
- C07D313/08—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pyrane Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662368526P | 2016-07-29 | 2016-07-29 | |
| PCT/US2017/044517 WO2018023072A2 (en) | 2016-07-29 | 2017-07-28 | Compounds and compositions and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3494119T3 true FI3494119T3 (fi) | 2024-12-05 |
Family
ID=61012362
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP17835385.0T FI3494119T3 (fi) | 2016-07-29 | 2017-07-28 | Yhdisteitä ja koostumuksia ja niiden käyttötapoja |
Country Status (26)
| Country | Link |
|---|---|
| US (4) | US10196403B2 (enExample) |
| EP (2) | EP3494119B1 (enExample) |
| JP (2) | JP7187437B2 (enExample) |
| KR (1) | KR102811121B1 (enExample) |
| CN (3) | CN110088107B (enExample) |
| AU (2) | AU2017301769B2 (enExample) |
| BR (1) | BR112019001439A8 (enExample) |
| CA (1) | CA3032302A1 (enExample) |
| DK (1) | DK3494119T3 (enExample) |
| EA (1) | EA201990400A1 (enExample) |
| ES (1) | ES2996835T3 (enExample) |
| FI (1) | FI3494119T3 (enExample) |
| HR (1) | HRP20241631T1 (enExample) |
| HU (1) | HUE070203T2 (enExample) |
| IL (1) | IL264446B2 (enExample) |
| LT (1) | LT3494119T (enExample) |
| MA (1) | MA45857A (enExample) |
| MX (2) | MX391221B (enExample) |
| MY (1) | MY199446A (enExample) |
| PH (1) | PH12019500196A1 (enExample) |
| PL (1) | PL3494119T3 (enExample) |
| PT (1) | PT3494119T (enExample) |
| SG (2) | SG11201900689RA (enExample) |
| SI (1) | SI3494119T1 (enExample) |
| UA (1) | UA125519C2 (enExample) |
| WO (1) | WO2018023072A2 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY199446A (en) | 2016-07-29 | 2023-10-28 | Sunovion Pharmaceuticals Inc | Compounds and compositions and uses thereof |
| WO2018023070A1 (en) | 2016-07-29 | 2018-02-01 | Sunovion Pharmaceuticals, Inc. | Compounds and compositions and uses thereof |
| KR20200036008A (ko) * | 2017-08-02 | 2020-04-06 | 선오비온 파마슈티컬스 인코포레이티드 | 이소크로만 화합물 및 이의 용도 |
| EP3870292A4 (en) | 2018-10-26 | 2022-11-09 | The Research Foundation for The State University of New York | COMBINATION OF SEROTONIN-SPECIFIC RESUPPUT INHIBITOR AND SEROTONIN 1A RECEPTOR PARTIAL AGONIST TO REDUCE L-DOPA-INDUCED DYSKINESIA |
| CN109369597B (zh) * | 2018-12-28 | 2022-11-29 | 陕西师范大学 | 一种异香豆素类化合物的合成方法 |
| CN113784755B (zh) | 2019-03-14 | 2024-05-10 | 赛诺维信制药公司 | 异色满基化合物的盐及其结晶形式、制备方法、治疗用途和药物组合物 |
| CN111122736B (zh) * | 2019-12-30 | 2021-03-12 | 北京鑫开元医药科技有限公司海南分公司 | 一种用于检测布瓦西坦中间体中对映异构体的方法 |
| WO2022217247A1 (en) * | 2021-04-08 | 2022-10-13 | Sunovion Pharmaceuticals Inc. | Isochroman derivatives and compositions and uses thereof |
| CN117177977A (zh) * | 2021-04-10 | 2023-12-05 | 住友制药株式会社 | 二环吡啶衍生物 |
| CA3214919A1 (en) * | 2021-04-10 | 2022-10-13 | Satoshi Adachi | Bicyclic pyridine derivative |
| US12077546B2 (en) | 2021-04-10 | 2024-09-03 | Sumitomo Pharma Co., Ltd. | Bicyclic pyridine derivative |
| CN115677719B (zh) * | 2022-10-27 | 2025-03-07 | 复旦大学 | 一种芳基并杂环化合物及其制备方法和用途 |
| CN119263959B (zh) * | 2024-12-10 | 2025-09-05 | 浙江九洲药业股份有限公司 | 一种格列齐特中间体1,2-环戊二甲醇的制备方法 |
| CN120518681B (zh) * | 2025-07-22 | 2025-09-12 | 成都施贝康生物医药科技有限公司 | 一种化合物及其应用 |
Family Cites Families (215)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB984365A (en) | 1961-10-03 | 1965-02-24 | Ici Ltd | Pyrimidine derivatives |
| US3470179A (en) | 1966-06-14 | 1969-09-30 | Sandoz Ag | 4-substituted-3,4-dihydroquinazolines |
| US3549624A (en) | 1967-08-17 | 1970-12-22 | Pfizer & Co C | 2-substituted-2-delta**2-tetrahydropyrimidines and delta**2-im |
| US3438995A (en) | 1968-01-08 | 1969-04-15 | Melville Sahyun | Diazaheterocyclic substituted benz-oxaheterocyclic compounds |
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3551427A (en) | 1969-05-09 | 1970-12-29 | Sandoz Ag | 4-thienyl-2-(1h)-quinazolones |
| US4021451A (en) * | 1972-05-16 | 1977-05-03 | American Home Products Corporation | Process for preparing polycyclic heterocycles having a pyran ring |
| US4036842A (en) | 1972-05-16 | 1977-07-19 | American Home Products Corporation | Process for preparing polycyclic heterocycles having a pyran ring |
| US4223151A (en) * | 1972-05-16 | 1980-09-16 | American Home Products Corporation | Process for preparing polycyclic heterocycles having a pyran ring |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| JPS51125287A (en) * | 1974-12-04 | 1976-11-01 | Takeda Chem Ind Ltd | Aprocess for preparing heterocyclic compounds |
| US4021452A (en) | 1975-04-23 | 1977-05-03 | American Cyanamid Company | 2,5-Dihydro-2,5-dialkoxyfuran derivatives |
| JPS541910Y2 (enExample) | 1975-12-12 | 1979-01-26 | ||
| JPS5919549B2 (ja) | 1976-01-01 | 1984-05-07 | 武田薬品工業株式会社 | 異節環状化合物 |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| GB1552004A (en) * | 1976-05-26 | 1979-09-05 | Takeda Chemical Industries Ltd | Isochroman derivatives |
| US4127665A (en) | 1978-01-18 | 1978-11-28 | Pfizer Inc. | Thienohydantoin derivatives |
| US4556656A (en) * | 1978-10-23 | 1985-12-03 | The Upjohn Company | 2-Benzoxepins |
| FR2459239A1 (fr) | 1979-06-20 | 1981-01-09 | Logeais Labor Jacques | Nouveaux derives amines du benzothiazole, leur procede de preparation et leur application en therapeutique |
| US4500543A (en) * | 1982-06-01 | 1985-02-19 | Abbott Laboratories | Substituted 1-aminomethyl-phthalans |
| US4518779A (en) * | 1982-09-27 | 1985-05-21 | Pennwalt Corporation | 1,2,3,4-Tetrahydro-1-aminomethyl-4-phenyl isoquinolines |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| PH30676A (en) | 1986-07-22 | 1997-09-16 | Boehringer Ingelhein Kg | Hetrazepine compounds which have useful pharmaceutical utility |
| JPH049367Y2 (enExample) | 1986-12-27 | 1992-03-09 | ||
| JPS646267A (en) * | 1987-02-04 | 1989-01-10 | Daiichi Seiyaku Co | 2-benzopyran derivative |
| US4904300A (en) | 1987-08-26 | 1990-02-27 | Ciba-Geigy Corp. | Imidazole derivatives |
| EP0333427B1 (en) | 1988-03-16 | 1995-08-23 | Smithkline Beecham Farmaceutici S.p.A. | Heterocyclic derivatives |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| DE3827727A1 (de) | 1988-08-16 | 1990-02-22 | Boehringer Ingelheim Kg | Anellierte tetrahydropyridinessigsaeurederivate, verfahren zu deren herstellung und verwendung solcher verbindungen zur kardioprotektion |
| GB8824400D0 (en) | 1988-10-18 | 1988-11-23 | Glaxo Group Ltd | Chemical compounds |
| EP0368175A1 (de) | 1988-11-06 | 1990-05-16 | Boehringer Ingelheim Kg | 3S,7S-3-(Morpholinocarbonyl)-5-(2-chlorphenyl)-7,10-dimethyl-3,4-dihydro-2H,7H-cyclopenta[4,5]thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin. |
| GB8827479D0 (en) | 1988-11-24 | 1988-12-29 | Zambeletti Spa L | Novel compounds |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| US4963568A (en) * | 1989-05-31 | 1990-10-16 | Abbott Laboratories | Dopamine agonists |
| US5621133A (en) | 1989-05-31 | 1997-04-15 | Deninno; Michael P. | Dopamine agonists |
| US4994486A (en) | 1989-05-31 | 1991-02-19 | Abbott Laboratories | Dopaminergic compounds |
| EP0416740A3 (en) | 1989-08-08 | 1991-08-28 | Beecham Group P.L.C. | Novel compounds with renin-inhibiting activity |
| JPH0735373B2 (ja) | 1989-08-11 | 1995-04-19 | 三共株式会社 | カルボン酸アミド化合物 |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| GB8926560D0 (en) | 1989-11-24 | 1990-01-17 | Zambeletti Spa L | Pharmaceuticals |
| DE3940477A1 (de) | 1989-12-07 | 1991-06-13 | Bayer Ag | Hetaryl-substituierte pyridinylpyrimidin-derivate |
| GB8927872D0 (en) | 1989-12-08 | 1990-02-14 | Beecham Group Plc | Pharmaceuticals |
| US5032598A (en) | 1989-12-08 | 1991-07-16 | Merck & Co., Inc. | Nitrogens containing heterocyclic compounds as class III antiarrhythmic agents |
| US5420151A (en) | 1989-12-22 | 1995-05-30 | Aktiebolaget Astra | Chroman derivatives |
| JPH03223277A (ja) | 1989-12-29 | 1991-10-02 | Yoshitomi Pharmaceut Ind Ltd | ベンゾチオフェン誘導体 |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| JPH0735373Y2 (ja) | 1990-02-22 | 1995-08-09 | 松下電器産業株式会社 | トランス |
| ZA912744B (en) | 1990-03-23 | 1992-02-26 | Zambeletti Spa L | Pharmaceuticals |
| JPH049367A (ja) | 1990-04-26 | 1992-01-14 | Zeria Pharmaceut Co Ltd | アリールアルカノイル誘導体，該化合物の製造中間体及びそれらを含有する医薬 |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5238939A (en) | 1990-05-25 | 1993-08-24 | Akzo N.V. | Isochromane derivatives |
| GB9018139D0 (en) | 1990-08-17 | 1990-10-03 | Pfizer Ltd | Therapeutic agents |
| NZ240155A (en) | 1990-10-29 | 1992-10-28 | Ishihara Sangyo Kaisha | Heterocyclyl acyl and (hexahydro) indanyl acyl substituted hydrazine derivatives, preparation thereof and pesticidal compositions |
| DE4104257A1 (de) | 1991-02-13 | 1992-08-20 | Boehringer Ingelheim Kg | Verwendung von anellierten tetrahydropyridinessigsaeurederivaten fuer die behandlung neurologischer erkrankungen |
| GB9104839D0 (en) | 1991-03-07 | 1991-04-17 | Zambeletti Spa L | Novel compounds |
| JPH0826011B2 (ja) * | 1991-04-25 | 1996-03-13 | アサヒビール株式会社 | アミノメチルイソクロマン誘導体およびその製造方法 |
| NZ243065A (en) | 1991-06-13 | 1995-07-26 | Lundbeck & Co As H | Piperidine derivatives and pharmaceutical compositions |
| US5288749A (en) * | 1991-12-20 | 1994-02-22 | Abbott Laboratories | Tertiary and secondary amines as alpha-2 antagonists and serotonin uptake inhibitors |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| PH31294A (en) | 1992-02-13 | 1998-07-06 | Thomae Gmbh Dr K | Benzimidazolyl derivatives, pharmaceutical compositions containing these compounds and process for preparing them. |
| JP3223277B2 (ja) | 1992-04-10 | 2001-10-29 | カシオ計算機株式会社 | 楽音制御装置 |
| FR2692264B1 (fr) | 1992-06-12 | 1994-08-05 | Adir | Nouvelles piperazines 1,4-disubstituees, leur procede de preparation et les compositions pharmaceutiques les contenant. |
| IT1255178B (it) | 1992-06-26 | 1995-10-20 | Pierrel Spa | N(eter0)-aril-n(etero)-tetralinalchil piperazine aventi attivita' serotoninergica,dopaminergica e adrenergica |
| DE59308842D1 (de) | 1992-12-02 | 1998-09-10 | Ciba Geigy Ag | Selektiv-herbizides Mittel |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| TW334423B (en) | 1993-10-22 | 1998-06-21 | Hoffmann La Roche | Tricyclic 1-aminoethylpyrrole-derivatives |
| JP3163068B2 (ja) | 1993-12-27 | 2001-05-08 | 日本建工株式会社 | 野縁取付け金具 |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| FR2723091B1 (fr) | 1994-07-29 | 1996-11-08 | Esteve Labor Dr | Tetrahydropyridine-(6,4-hydroxypiperidine) alkylazoles |
| WO1996038435A1 (en) * | 1995-05-30 | 1996-12-05 | Abbott Laboratories | Dopamine agonists |
| FR2734819B1 (fr) | 1995-05-31 | 1997-07-04 | Adir | Nouveaux composes de la piperazine, de la piperidine et de la 1,2,5,6-tetrahydropyridine, leur procede de preparation et les compositions pharmaceutiques les contenant |
| SE9702563D0 (sv) | 1997-07-02 | 1997-07-02 | Astra Ab | Compounds |
| DE19751949A1 (de) | 1997-11-24 | 1999-05-27 | Bayer Ag | Verwendung von substituierten Aminomethyl-Chromanen zur Verhinderung der neuronalen Degeneration und zur Förderung der neuronalen Regeneration |
| WO1999046267A1 (en) | 1998-03-12 | 1999-09-16 | Novo Nordisk A/S | Modulators of protein tyrosine phosphatases (ptpases) |
| US6262044B1 (en) | 1998-03-12 | 2001-07-17 | Novo Nordisk A/S | Modulators of protein tyrosine phosphatases (PTPASES) |
| KR20010041811A (ko) | 1998-03-12 | 2001-05-25 | 온토젠 코포레이션 | 단백질 티로신 포스파타제의 조절제 |
| CN1300291A (zh) | 1998-03-12 | 2001-06-20 | 诺沃挪第克公司 | 蛋白质酪氨酸磷酸酶(ptp酶)的调节物 |
| DE19817262A1 (de) | 1998-04-18 | 1999-10-21 | Bayer Ag | Neue 2-heterocyclisch substituierte Dihydropyrimidine |
| DE19817265A1 (de) | 1998-04-18 | 1999-10-21 | Bayer Ag | Verwendung von Dihydropyrimidinen als Arzneimittel und neue Stoffe |
| JP2002519348A (ja) | 1998-06-30 | 2002-07-02 | イーライ・リリー・アンド・カンパニー | ５−ｈｔ１ｆアゴニスト |
| AU6325599A (en) | 1998-10-21 | 2000-05-08 | Dr. Reddy's Research Foundation | New compounds, their preparation and use |
| JP3454427B2 (ja) | 1998-12-14 | 2003-10-06 | 藤沢薬品工業株式会社 | ピペラジン誘導体 |
| EP1147113B1 (en) | 1999-01-19 | 2006-06-07 | Neurosearch A/S | Fused heterocyclic compounds and their use in the treatment of neurodegenerative diseases |
| US6313309B1 (en) | 1999-04-05 | 2001-11-06 | Ortho-Mcneil Pharmaceutical, Inc. | 4-thionaphthyl—1H—imidazoles which are usefulα22-adrenoceptoR agonists/ antagonists |
| AU4589800A (en) | 1999-05-05 | 2000-11-21 | Darwin Discovery Limited | 9-(1,2,3,4-tetrahydronaphthalen-1-yl)-1,9-dihydropurin-6-one derivatives as pde7inhibitors |
| GB9914025D0 (en) | 1999-06-17 | 1999-08-18 | Zeneca Ltd | Chemical compounds |
| WO2001019831A1 (en) | 1999-09-10 | 2001-03-22 | Novo Nordisk A/S | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases) |
| AU7476800A (en) | 1999-09-10 | 2001-04-10 | Novo Nordisk A/S | Method of inhibiting protein tyrosine phosphatase 1b and/or t-cell protein tyrosine phosphatase and/or other ptpases with an asp residue at position 48 |
| WO2001032610A1 (en) | 1999-10-29 | 2001-05-10 | Kaken Pharmaceutical Co., Ltd. | Urea derivative, process for producing the same, and medicine containing the urea derivative |
| AR030537A1 (es) | 1999-11-05 | 2003-08-27 | Abbott Lab | Acidos quinolincarboxilicos y naftiridincarboxilico antibacterianos |
| CA2398274C (en) | 2000-02-25 | 2009-09-22 | F. Hoffmann-La Roche Ag | Adenosine receptor modulators |
| AU4262901A (en) | 2000-03-29 | 2001-10-08 | Cyclacel Ltd | 2-substituted 4-heteroaryl-pyrimidines and their use in the treatmetn of proliferative disorders |
| EP1510222A3 (en) | 2000-04-26 | 2007-05-23 | Eisai R&D Management Co., Ltd. | Medicinal compositions promoting bowel movement |
| AU2001277731A1 (en) | 2000-08-09 | 2002-02-18 | Welfide Corporation | Fused bicyclic amide compounds and medicinal use thereof |
| AU2001286191A1 (en) | 2000-09-12 | 2002-03-26 | Sankyo Company, Limited | Quinolizine derivatives |
| US6660731B2 (en) | 2000-09-15 | 2003-12-09 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| WO2002066443A2 (en) | 2001-02-21 | 2002-08-29 | Ono Pharmaceutical Co., Ltd. | 2-thioxo-1,2,3,4-tetrahydropyrimidine derivatives |
| US6642227B2 (en) | 2001-04-13 | 2003-11-04 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases |
| WO2002102387A1 (en) | 2001-06-18 | 2002-12-27 | H. Lundbeck A/S | Treatment of neuropathic pain |
| ATE284878T1 (de) | 2001-07-11 | 2005-01-15 | Lilly Co Eli | Pharmazeutische verbindungen mit serotonin rezeptor aktivität |
| US20040180883A1 (en) | 2001-07-11 | 2004-09-16 | Jeremy Gilmore | Pharmaceutical compounds with serotonin receptor activity |
| EP1441725A1 (en) | 2001-10-26 | 2004-08-04 | Aventis Pharmaceuticals Inc. | Benzimidazoles and analogues and their use as protein kinases inhibitors |
| JP2003261566A (ja) | 2002-03-11 | 2003-09-19 | Sankyo Co Ltd | キノリジンを含有する医薬 |
| RS50905B (sr) | 2002-04-10 | 2010-08-31 | Dongbu Hannong Chemical Co.Ltd. | Derivati benzopirana supstituisani sa sekundarnim aminima uključujući tetrazol, postupak za njihovo dobijanje i farmaceutske kompozicije koje ih sadrže |
| TW200306783A (en) | 2002-04-29 | 2003-12-01 | Fmc Corp | Pesticidal heterocycles |
| US7358269B2 (en) | 2002-05-21 | 2008-04-15 | Allergan, Inc. | 2-((2-Thioxo-2,3-dihydro-1H-imidazol-4-yl)methyl)-3,4-dihydronapthalen-1(2H)-one |
| US7091232B2 (en) | 2002-05-21 | 2006-08-15 | Allergan, Inc. | 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds |
| US7276522B2 (en) | 2002-05-21 | 2007-10-02 | Allergan, Inc. | 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones, 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds |
| US7323485B2 (en) | 2002-05-21 | 2008-01-29 | Allergan, Inc. | 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds |
| SE0202134D0 (sv) | 2002-07-08 | 2002-07-08 | Astrazeneca Ab | Therapeutic agents |
| EP2156830A1 (en) | 2002-10-16 | 2010-02-24 | Isis Innovation Limited | Modulators of asparaginyl hydoxylase activity of FIH |
| EP1587482A4 (en) | 2003-01-31 | 2010-08-25 | Technion Res & Dev Foundation | INFLAMMATORY COMPOSITIONS AND ITS USES |
| EP1602647B1 (en) | 2003-03-07 | 2013-10-16 | Santen Pharmaceutical Co., Ltd. | Novel compound having 4-pyridylalkylthio group as substituent |
| JP2004269449A (ja) | 2003-03-11 | 2004-09-30 | Ishihara Sangyo Kaisha Ltd | ベンズアミド誘導体、それらの製造方法及びそれらを含有する有害生物防除剤 |
| US7205318B2 (en) | 2003-03-18 | 2007-04-17 | Bristol-Myers Squibb Company | Lactam-containing cyclic diamines and derivatives as a factor Xa inhibitors |
| EP1611109A4 (en) | 2003-03-31 | 2009-06-24 | Taisho Pharmaceutical Co Ltd | NOVEL QUINAZOLINE DERIVATIVES AND THEIR THERAPEUTIC USE |
| AU2004226824B2 (en) | 2003-04-04 | 2008-05-01 | Novartis Ag | Quinoline-2-one-derivatives for the treatment of airways diseases |
| GB0308466D0 (en) | 2003-04-11 | 2003-05-21 | Novartis Ag | Organic compounds |
| WO2004112719A2 (en) | 2003-06-19 | 2004-12-29 | Smithkline Beecham Corporation | Chemical compounds |
| US20050032873A1 (en) | 2003-07-30 | 2005-02-10 | Wyeth | 3-Amino chroman and 2-amino tetralin derivatives |
| DE10347385A1 (de) | 2003-10-08 | 2005-05-12 | Schering Ag | Umgelagerte Pentanole, ein Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer |
| JP2005145859A (ja) | 2003-11-13 | 2005-06-09 | Nippon Steel Chem Co Ltd | 脱水素化方法及び芳香族複素環化合物の製造方法 |
| DE10360793A1 (de) | 2003-12-23 | 2005-07-28 | Grünenthal GmbH | Spirocyclische Cyclohexan-Derivate |
| CA2553670A1 (en) | 2004-01-29 | 2005-08-11 | Elixir Pharmaceuticals, Inc. | Anti-viral therapeutics |
| DE102004004974A1 (de) | 2004-01-31 | 2005-08-18 | Aventis Pharma Deutschland Gmbh | Thieno-Iminosäure-Derivate als Inhibitoren von Matrix-Metalloproteinasen |
| GB0403155D0 (en) | 2004-02-12 | 2004-03-17 | Vernalis Res Ltd | Chemical compounds |
| US20050239832A1 (en) | 2004-03-09 | 2005-10-27 | Varghese John | Methods of treatment of amyloidosis using bi-cyclic aspartyl protease inhibitors |
| KR100553398B1 (ko) | 2004-03-12 | 2006-02-16 | 한미약품 주식회사 | 티에노[3,2-ｃ]피리딘 유도체의 제조 방법 및 이에사용되는 중간체 |
| US7544717B2 (en) | 2004-03-25 | 2009-06-09 | Elan Pharmaceuticals, Inc. | 2-amino- and 2-thio- substituted 1,3-diaminopropanes |
| JP4685861B2 (ja) | 2004-04-29 | 2011-05-18 | アベンティス・ファーマスーティカルズ・インコーポレイテツド | ドーパミンアゴニストとしての３−ピペリジニルイソクロマン−５−オール |
| WO2006015259A2 (en) | 2004-07-28 | 2006-02-09 | Irm Llc | Compounds and compositions as modulators of steroid hormone nuclear receptors |
| SE0401971D0 (sv) | 2004-08-02 | 2004-08-02 | Astrazeneca Ab | Piperidne derivatives |
| SE0401970D0 (sv) | 2004-08-02 | 2004-08-02 | Astrazeneca Ab | Novel compounds |
| EP1634873A1 (en) | 2004-08-27 | 2006-03-15 | Laboratorios Del Dr. Esteve, S.A. | Sigma receptor inhibitors |
| FR2875230A1 (fr) | 2004-09-13 | 2006-03-17 | Sanofi Aventis Sa | Derives de pyrazole condense, leur preparation et leur application en therapeutique |
| JP2006117568A (ja) | 2004-10-20 | 2006-05-11 | Mitsubishi Pharma Corp | チオフェン環を有する新規アミド誘導体及びその医薬としての用途 |
| US7214704B2 (en) | 2004-11-15 | 2007-05-08 | Bristol-Myers Squibb Company | 2-Amino-1-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors |
| CN101115749B (zh) | 2004-12-17 | 2011-06-22 | 安姆根有限公司 | 氨基嘧啶化合物和使用方法 |
| DE102004063227A1 (de) | 2004-12-22 | 2006-07-06 | Schering Ag | Tricylische Aminoalkohole, Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer |
| EP1856126A2 (en) | 2005-02-17 | 2007-11-21 | Wyeth a Corporation of the State of Delaware | Cycloalkylfused indole, benzothiophene, benzofuran and indene derivatives |
| US7884109B2 (en) | 2005-04-05 | 2011-02-08 | Wyeth Llc | Purine and imidazopyridine derivatives for immunosuppression |
| GT200600166A (es) | 2005-04-22 | 2007-03-14 | Derivados de cromano y cromeno y usos de los mismos | |
| KR20070121013A (ko) | 2005-04-22 | 2007-12-26 | 다이이찌 산쿄 가부시키가이샤 | 헤테로 고리 화합물 |
| WO2006117305A1 (en) | 2005-05-04 | 2006-11-09 | F. Hoffmann-La Roche Ag | (3,4-dihydro-quinazolin-2-yl)-(2-aryloxy-ethyl)-amines having an activity on the 5-ht receptor |
| CN101228121A (zh) * | 2005-05-23 | 2008-07-23 | 阿斯利康(瑞典)有限公司 | 调节5ht6受体的新的8-磺酰基-3-氨基取代的苯并二氢吡喃或四氢化萘衍生物 |
| WO2007002681A2 (en) | 2005-06-27 | 2007-01-04 | E. I. Du Pont De Nemours And Company | Electrically conductive polymer compositions |
| WO2007001939A1 (en) | 2005-06-27 | 2007-01-04 | Janssen Pharmaceutica N.V. | Tetrahydro-pyranopyrazole compounds displaying cannabinoid modulating activities |
| US20100168102A9 (en) | 2005-07-11 | 2010-07-01 | Devgen Nv | Amide Derivatives as Kinase Inhibitors |
| US7598255B2 (en) | 2005-08-04 | 2009-10-06 | Janssen Pharmaceutica Nv | Pyrimidine compounds as serotonin receptor modulators |
| TW200800201A (en) | 2005-11-18 | 2008-01-01 | Lilly Co Eli | Pyrimidinyl benzothiophene compounds |
| US7745484B2 (en) | 2005-11-21 | 2010-06-29 | Amgen Inc. | Beta-secretase modulators and methods of use |
| WO2007095586A2 (en) | 2006-02-14 | 2007-08-23 | The Trustees Of Columbia University In The City Of New York | Neuronal pain pathway modulators |
| US20090264470A1 (en) | 2006-02-21 | 2009-10-22 | Bennett Teresa A | CB1 Antagonists and Inverse Agonists |
| EP1829869A1 (en) | 2006-03-02 | 2007-09-05 | Laboratorios Del Dr. Esteve, S.A. | 4,5,6,7-Tetrahydrobenzo[b]thiophene derivatives and their use as sigma receptor ligands |
| BRPI0709817A2 (pt) | 2006-04-12 | 2011-07-26 | Wyeth Corp | composto da fàrmula i; mÉtodo para o tratamento de um distérbio do sistema nervoso central relacionado ou afetado pelo receptor de 5-ht6 em um paciente que necessita deste; composiÇço farmacÊutica; e processo para a preparaÇço de um composto da fàrmula i |
| JPWO2007126041A1 (ja) | 2006-04-28 | 2009-09-10 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ベンゾイソオキサゾール化合物 |
| US20080021217A1 (en) | 2006-07-20 | 2008-01-24 | Allen Borchardt | Heterocyclic inhibitors of rho kinase |
| AU2007305269A1 (en) | 2006-10-04 | 2008-04-10 | Schering Corporation | Bicyclic and tricyclic derivatives as thrombin receptor antagonists |
| US7960569B2 (en) | 2006-10-17 | 2011-06-14 | Bristol-Myers Squibb Company | Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
| AU2007321720A1 (en) | 2006-11-15 | 2008-05-22 | Genetic Technologies Limited | Compounds, compositions and methods for controlling invertebrate pests |
| WO2009008906A2 (en) | 2007-02-06 | 2009-01-15 | The Trustees Of The University Of Pennsylvania | Therapeutic compounds for blocking dna synthesis of pox viruses |
| JP5283846B2 (ja) | 2007-02-09 | 2013-09-04 | 三菱レイヨン株式会社 | 成形体とその製造方法 |
| EP2111231A4 (en) | 2007-02-13 | 2010-12-15 | Univ Northeastern | METHOD AND COMPOSITIONS FOR IMPROVING IMMUNE REACTIONS |
| US8012986B2 (en) | 2007-04-02 | 2011-09-06 | Hoffmann-La Roche Inc. | Pyridine and pyrimidine derivatives as MGLUR2 antagonists |
| US7598417B2 (en) | 2007-04-12 | 2009-10-06 | Allergan, Inc. | Substituted fluoroethyl ureas as alpha 2 adrenergic agents |
| EP1982987A1 (en) | 2007-04-16 | 2008-10-22 | Laboratorios del Dr. Esteve S.A. | Spiro-pyrano-pyrazole derivatives |
| EP1982714A1 (en) | 2007-04-16 | 2008-10-22 | Laboratorios del Dr. Esteve S.A. | Pyrano-pyrazole-amines |
| EP2020414A1 (en) | 2007-06-20 | 2009-02-04 | Laboratorios del Dr. Esteve S.A. | spiro[piperidine-4,4'-thieno[3,2-c]pyran] derivatives and related compounds as inhibitors of the sigma receptor for the treatment of psychosis |
| US8338623B2 (en) | 2007-07-09 | 2012-12-25 | Abbvie Inc. | Compounds as cannabinoid receptor ligands |
| US8022209B2 (en) | 2007-09-12 | 2011-09-20 | Janssen Pharmaceutica Nv | Substituted nitrogen-containing heteroaryl derivatives useful as modulators of the histamine H4 receptor |
| KR101103118B1 (ko) | 2007-11-02 | 2012-01-04 | 동아제약주식회사 | 신규한 1,3-디히드로-5-이소벤조퓨란카르보니트릴 유도체 화합물 및 이를 함유하는 조루증 치료용 약학조성물 |
| ES2469824T3 (es) | 2007-11-21 | 2014-06-20 | Janssen Pharmaceutica N.V. | Espiropiperidinas para su uso como inhibidores de la triptasa |
| US7973051B2 (en) | 2007-11-30 | 2011-07-05 | Hoffman-La Roche Inc. | Aminothiazoles as FBPase inhibitors for diabetes |
| JPWO2009072621A1 (ja) | 2007-12-07 | 2011-04-28 | 日産化学工業株式会社 | 置換ジヒドロアゾール化合物及び有害生物防除剤 |
| CN101468986B (zh) | 2007-12-26 | 2010-12-29 | 香港南北兄弟国际投资有限公司 | 一种二氢嘧啶消旋化合物的拆分方法 |
| CN101468987B (zh) | 2007-12-26 | 2011-06-08 | 香港南北兄弟国际投资有限公司 | 2-杂环取代的二氢嘧啶消旋化合物的拆分方法 |
| WO2009085256A1 (en) | 2007-12-27 | 2009-07-09 | Panacos Pharmaceuticals, Inc. | Anti-hiv compounds |
| CN101759710B (zh) | 2008-10-06 | 2011-10-05 | 山东轩竹医药科技有限公司 | 含有取代的氮杂环的头孢菌素衍生物 |
| US9776963B2 (en) | 2008-11-10 | 2017-10-03 | The Trustees Of The University Of Pennsylvania | Small molecule CD4 mimetics and uses thereof |
| US9139589B2 (en) | 2009-01-30 | 2015-09-22 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| AR075442A1 (es) | 2009-02-16 | 2011-03-30 | Abbott Gmbh & Co Kg | Derivados de aminotetralina, composiciones farmaceuticas que las contienen y sus usos en terapia |
| TW201038569A (en) | 2009-02-16 | 2010-11-01 | Abbott Gmbh & Co Kg | Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy |
| US8673920B2 (en) * | 2009-05-06 | 2014-03-18 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| TW201041757A (en) | 2009-05-20 | 2010-12-01 | Univ Nat Taiwan Science Tech | Method for simulating, fabricating or duplicating an oil painting |
| JP2013501068A (ja) | 2009-08-05 | 2013-01-10 | アイディニックス ファーマシューティカルズ インコーポレイテッド | 大環状セリンプロテアーゼ阻害剤 |
| WO2011036889A1 (ja) | 2009-09-25 | 2011-03-31 | 武田薬品工業株式会社 | 複素環化合物 |
| UA107943C2 (xx) | 2009-11-16 | 2015-03-10 | Lilly Co Eli | Сполуки спіропіперидину як антагоністи рецептора orl-1 |
| PT2501704E (pt) | 2009-11-16 | 2013-12-05 | Lilly Co Eli | Compostos de espiropiperidina como antagonistas do receptor orl-1 |
| MX388468B (es) | 2009-12-04 | 2025-03-20 | Sunovion Pharmaceuticals Inc | Compuestos multicíclicos y métodos de uso de los mismos. |
| AU2010339271B2 (en) | 2009-12-28 | 2015-09-03 | General Incorporated Association Pharma Valley Project Supporting Organization | 1,3,4-oxadiazole-2-carboxamide compound |
| AU2011210518A1 (en) | 2010-02-01 | 2012-07-19 | Sgl Carbon Se | Defensive, ceramic based, applique armor, device for providing anti-projectile armoring protection and process for producing ceramic based projectile armor with hollow geometry |
| EP2377850A1 (en) | 2010-03-30 | 2011-10-19 | Pharmeste S.r.l. | TRPV1 vanilloid receptor antagonists with a bicyclic portion |
| WO2011133729A2 (en) | 2010-04-23 | 2011-10-27 | Kineta, Inc. | Anti-viral compounds |
| US9051280B2 (en) | 2010-08-13 | 2015-06-09 | AbbVie Deutschland GmbH & Co. KG | Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy |
| US8883839B2 (en) | 2010-08-13 | 2014-11-11 | Abbott Laboratories | Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy |
| MX2013006858A (es) | 2010-12-16 | 2013-07-29 | Hoffmann La Roche | Compuesto triciclicos inhibidores de la pi3k y metodos de uso. |
| EP2683710B1 (en) | 2011-03-10 | 2017-07-19 | Boehringer Ingelheim International GmbH | Soluble guanylate cyclase activators |
| CN102731574B (zh) | 2011-03-30 | 2016-03-02 | 中国人民解放军军事医学科学院毒物药物研究所 | 噻吩并吡啶类α-胺基苄基膦酸酯、其制备方法及用途 |
| WO2013010453A1 (en) | 2011-07-15 | 2013-01-24 | Abbott Laboratories | Chemoking receptor antagonists |
| WO2013067248A1 (en) | 2011-11-04 | 2013-05-10 | Vertex Pharmaceuticals Incorporated | Benzoxazines as modulators of ion channels |
| CA2864085C (en) | 2012-02-08 | 2021-11-23 | Sunovion Pharmaceuticals Inc. | Heteroaryl compounds and methods of use thereof |
| EP2863912A4 (en) | 2012-06-20 | 2015-11-04 | Univ Vanderbilt | SUBSTITUTED BICYCLIC ALKOXYPYRAZOL ANALOGUES AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS |
| RU2664541C2 (ru) | 2012-11-13 | 2018-08-20 | Эррэй Биофарма Инк. | Бициклические соединения мочевины, тиомочевины, гуанидина и цианогуанидина, пригодные для лечения боли |
| JP6359560B2 (ja) | 2012-12-31 | 2018-07-18 | サノビオン ファーマシューティカルズ インクＳｕｎｏｖｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． | 複素環式化合物及びその使用方法 |
| JP2014214130A (ja) | 2013-04-26 | 2014-11-17 | 大正製薬株式会社 | ジヒドロイミダゾオキサゾール誘導体を含有する医薬 |
| EP3256466B9 (en) * | 2015-02-11 | 2022-07-27 | Sunovion Pharmaceuticals Inc. | 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders |
| MX371197B (es) | 2015-02-11 | 2020-01-22 | Sunovion Pharmaceuticals Inc | Compuestos de dihidro-4h-pirazolo [5,1-c] [1,4] oxazinilo y análogos para el tratamiento de trastornos del sistema nervioso central (snc). |
| MY199446A (en) | 2016-07-29 | 2023-10-28 | Sunovion Pharmaceuticals Inc | Compounds and compositions and uses thereof |
| WO2018023070A1 (en) | 2016-07-29 | 2018-02-01 | Sunovion Pharmaceuticals, Inc. | Compounds and compositions and uses thereof |
| GB2560198B (en) | 2017-03-03 | 2020-10-07 | Guala Closures Int B V | Tamper evident closure |
| KR20200036008A (ko) * | 2017-08-02 | 2020-04-06 | 선오비온 파마슈티컬스 인코포레이티드 | 이소크로만 화합물 및 이의 용도 |
| CN113784755B (zh) | 2019-03-14 | 2024-05-10 | 赛诺维信制药公司 | 异色满基化合物的盐及其结晶形式、制备方法、治疗用途和药物组合物 |
| WO2022217247A1 (en) * | 2021-04-08 | 2022-10-13 | Sunovion Pharmaceuticals Inc. | Isochroman derivatives and compositions and uses thereof |
-
2017
- 2017-07-28 MY MYPI2019000466A patent/MY199446A/en unknown
- 2017-07-28 JP JP2019504697A patent/JP7187437B2/ja active Active
- 2017-07-28 SI SI201731570T patent/SI3494119T1/sl unknown
- 2017-07-28 IL IL264446A patent/IL264446B2/en unknown
- 2017-07-28 BR BR112019001439A patent/BR112019001439A8/pt active IP Right Grant
- 2017-07-28 AU AU2017301769A patent/AU2017301769B2/en active Active
- 2017-07-28 SG SG11201900689RA patent/SG11201900689RA/en unknown
- 2017-07-28 HU HUE17835385A patent/HUE070203T2/hu unknown
- 2017-07-28 EA EA201990400A patent/EA201990400A1/ru unknown
- 2017-07-28 ES ES17835385T patent/ES2996835T3/es active Active
- 2017-07-28 MA MA045857A patent/MA45857A/fr unknown
- 2017-07-28 EP EP17835385.0A patent/EP3494119B1/en active Active
- 2017-07-28 KR KR1020197006310A patent/KR102811121B1/ko active Active
- 2017-07-28 UA UAA201901971A patent/UA125519C2/uk unknown
- 2017-07-28 MX MX2019000980A patent/MX391221B/es unknown
- 2017-07-28 EP EP24189877.4A patent/EP4464317A3/en active Pending
- 2017-07-28 CN CN201780059514.6A patent/CN110088107B/zh active Active
- 2017-07-28 US US15/663,688 patent/US10196403B2/en active Active
- 2017-07-28 HR HRP20241631TT patent/HRP20241631T1/hr unknown
- 2017-07-28 LT LTEPPCT/US2017/044517T patent/LT3494119T/lt unknown
- 2017-07-28 PT PT178353850T patent/PT3494119T/pt unknown
- 2017-07-28 CN CN202310305282.5A patent/CN116283877A/zh active Pending
- 2017-07-28 SG SG10202100724UA patent/SG10202100724UA/en unknown
- 2017-07-28 FI FIEP17835385.0T patent/FI3494119T3/fi active
- 2017-07-28 WO PCT/US2017/044517 patent/WO2018023072A2/en not_active Ceased
- 2017-07-28 PL PL17835385.0T patent/PL3494119T3/pl unknown
- 2017-07-28 DK DK17835385.0T patent/DK3494119T3/da active
- 2017-07-28 CA CA3032302A patent/CA3032302A1/en active Pending
- 2017-07-28 CN CN202310301034.3A patent/CN116514761A/zh active Pending
-
2018
- 2018-12-10 US US16/214,985 patent/US10927124B2/en active Active
-
2019
- 2019-01-23 MX MX2022003907A patent/MX2022003907A/es unknown
- 2019-01-28 PH PH12019500196A patent/PH12019500196A1/en unknown
-
2021
- 2021-01-11 US US17/145,548 patent/US11958862B2/en active Active
-
2022
- 2022-08-10 JP JP2022128312A patent/JP7402284B2/ja active Active
- 2022-10-05 AU AU2022246388A patent/AU2022246388B2/en active Active
-
2024
- 2024-03-15 US US18/605,922 patent/US20240409550A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3494119T3 (fi) | Yhdisteitä ja koostumuksia ja niiden käyttötapoja | |
| JP2009509921A5 (enExample) | ||
| FI3784283T3 (fi) | Kannabidiolivalmisteita ja niiden käyttöjä | |
| ES2735422T3 (es) | Imidazopirazinonas como inhibidores de PDE1 | |
| JP2014508756A5 (enExample) | ||
| RU2010123781A (ru) | Производные 4-(2-фенил)-морфолино)-2-оксопирролидин-1-ил)-n-(тиазол-2-ил)бензолсульфонамида и родственные соединения в качестве модуляторов ионных каналов для лечения боли | |
| EP3490607A1 (en) | Compounds and compositions and uses thereof | |
| ES2538998T3 (es) | Compuestos con actividad antibacteriana contra Clostridium | |
| NZ750207B2 (en) | Compounds and compositions and uses thereof | |
| NZ790740A (en) | Compounds and compositions and uses thereof | |
| US20240417382A1 (en) | Salts of a heterocyclic compound and crystalline forms, processes for preparing, therapeutic uses, and pharmaceutical compositions thereof | |
| NZ790740B2 (en) | Compounds and compositions and uses thereof | |
| Zhang et al. | Facile and stereo-controlled synthesis of 2-deoxynojirimycin, Miglustat and Miglitol | |
| WO2009001356A3 (en) | Acyl-urea derivatives and uses thereof | |
| US20240182436A1 (en) | Substituted sulfonamide-chroman compounds, and pharmaceutical compositions, and methods of use thereof | |
| AU2020236225B2 (en) | Salts of a isochromanyl compound and crystalline forms, processes for preparing, therapeutic uses, and pharmaceutical compositions thereof | |
| US9580394B2 (en) | Benzodiazepine derivative and method of producing the same | |
| JP2016531860A (ja) | Ｍｇｌｕ５受容体のネガティブアロステリック調節因子の多型 | |
| EA044010B1 (ru) | Соединения и композиции и их применение | |
| TN2010000565A1 (en) | Compounds comprising a cyclobutoxy group |